Table 1 Patient characteristics and association with baseline mTBI (N = 20)
Characteristic | N (%) | Baseline mTBI (%) Median (IQR) | P Value |
|---|---|---|---|
All patients | 20 | Â | Â |
Age (years), median | 60 (34–76) |  |  |
Age group | |||
 < 60 | 11 (55.0) | 3.62 (0.90–27.54) | – |
 60+ | 9 (45.0) | 23.79 (4.11–48.52) | 0.2601 |
Gender | |||
 Female | 6 (30.0) | 3.24 (0.00–4.11) | – |
 Male | 14 (70.0) | 38.72 (6.80–57.99) | 0.0111 |
ECOG | |||
 0 | 15 (75.0) | 5.00 (1.24–38.72) | – |
 1 | 5 (25.0) | 45.52 (6.37–73.77) | 0.0978 |
Primary tumor site | |||
 Left-side colon | 16 (80.0) | 9.01 (1.38–44.57) | – |
 Right-side colon | 4 (20.0) | 13.71 (3.34–60.85) | 0.8198 |
Synchronicity of metastasis | |||
 Metachrone | 10 (50.0) | 12.49 (1.65–45.9) | – |
 Synchrone | 10 (50.0) | 7.20 (2.43–46.3) | 1.0000 |
Primary tumor(s) | |||
 Resected | 15 (75.0) | 5.00 (1.79–38.72) | – |
 Unresected | 5 (25.0) | 41.70 (4.70–59.36) | 0.3941 |
Metastatic site(s) | |||
 1 without peritoneum | 9 (45.0) | 9.40 (2.24–47.02) | – |
 2+ without peritoneum | 11 (55.0) | 8.62 (1.79–38.72) | 0.8817 |
 Peritoneum | 0 |  | – |
Baseline serum CEA | |||
 Normal | 5 (25.0) | 1.79 (0.62–13.52) | – |
 Elevated | 15 (75.0) | 16.36 (4.11–48.52) | 0.0522 |
Chemotherapy regimen | |||
 FOLFOX | 15 (75.0) | 8.62 (3.24–45.52) | – |
 FOLFIRI | 5 (25.0) | 16.36 (1.52–51.94) | 0.9327 |
Bevacizumab received | |||
 Yes | 1 (5.0) | 23.79 | – |
 No | 19 (95.0) | 8.62 (1.79–45.52) | – |